Apathy in Dementia Methylphenidate Trial 2

ADMET 2 will examine in a masked, randomized trial the efficacy of methylphenidate for the
treatment of clinically significant apathy in participants with Alzheimer's dementia.
Efficacy will be assessed as the change in Neuropsychiatric Inventory Apathy subscale (NPI
apathy) from baseline to 6 months and score on the Alzheimer's Disease Cooperative Study -
Clinical Global Impression of Change (CGIC) scale at 6 months.

ADMET 2 will also examine the safety of methylphenidate for the treatment of clinically
significant apathy in participants with Alzheimer's disease by measuring vital signs,
electrolyte panels, adverse event reports, and electrocardiograms. Safety will also be
measured by examining neuropsychiatric symptoms other than apathy using the Neuropsychiatric
Inventory (NPI).

Changes from baseline to 6 months in other neuropsychological assessments as measured using
the Dementia Apathy Interview and Rating (DAIR) scale will also be assessed.

Cost-effectiveness will be measured by assessing quality of life and economic assessment and
cognitive changes using a cognitive battery that includes the Mini Mental State Exam (MMSE)
and other scales.

A biomarker sub-study initiated part-way through the main trial will collect information on
blood-based biomarkers, including microRNA, markers of oxidative stress, inflammation,
neuronal loss and lipidomics.

Inclusion criteria

- Possible or probable Alzheimer's disease (National Institute of Neurological and
Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders
Association (NINCDS-ADRDA) criteria), with Mini-Mental State Exam (MMSE) score of
10-28 inclusive

- Clinically significant apathy for at least four weeks for which either

- the frequency of apathy as assessed by the Neuropsychiatric Inventory (NPI) is
'Very frequently', or

- the frequency of apathy as assessed by the NPI is 'Frequently' or 'Often' AND the
severity of apathy as assessed by the NPI is 'Moderate' or 'Marked'

- A medication for apathy is appropriate, in the opinion of the study physician

- Provision of informed consent for participation in the study by potential participant
or surrogate (with participant assent if the potential participant is unable to
provide informed consent) and caregiver

- Availability of primary caregiver, who spends greater than ten hours a week with the
potential participant and supervises his/her care, to accompany the potential
participant to study visits and to participate in the study

- Sufficient fluency, of both the potential participant and caregiver, in written and
spoken English to participate in study visits, physical exams, and outcome assessments

- If female, woman must be post-menopausal for at least 2 years or have had a
hysterectomy

Exclusion criteria

- Currently meets criteria for Major Depressive Episode, by Diagnostic Statistical
Manual of Mental Disorder - IV (TR) criteria

- Clinically significant agitation /aggression for which either

- the frequency of agitation /aggression as assessed by the NPI is 'Very
frequently', or

- the frequency of agitation /aggression as assessed by the NPI is 'Frequently' AND
the severity of the agitation as assessed by the NPI is 'Moderate', or 'Marked'

- Clinically significant delusions for which either

- the frequency of delusions as assessed by the NPI is 'Very frequently', or

- the frequency of delusions as assessed by the NPI is 'Frequently' AND the
severity of the delusions as assessed by the NPI is 'Moderate', or 'Marked'

- Clinically significant hallucinations for which either

- the frequency of hallucinations as assessed by the NPI is 'Very frequently', or

- the frequency of hallucinations as assessed by the NPI is 'Frequently' AND the
severity of the hallucinations as assessed by the NPI is 'Moderate', or 'Marked'

- Change to AD medications within the month preceding randomization, including starting,
stopping, or dosage modifications

- Change in anti-depressant (except for trazodone used for sleeping difficulties as
described below) use within the 30 days preceding randomization or a period of time
equal to 5 half-lives of drug, whichever period of time is longer

- Use of trazodone > 50mg or lorazepam > 0.5mg or for indications other than sleeping
difficulties within the 30 days preceding randomization or a period of time equal to 5
half-lives of drug, whichever period of time is longer. Other benzodiazepines are
prohibited in the past 30 days or within 5 half-lives, whichever period of time is
longer.

- Failure of treatment with methylphenidate in the past for apathy after convincing
evidence of an adequate trial as judged by study physician

- Currently taking any amphetamine product, an antipsychotic, bupropion, or any
medication that would prohibit the safe concurrent use of methylphenidate, including
but not limited to monoamine oxidase inhibitors and tricyclic antidepressants within
the 30 days preceding randomization or a period of time equal to 5 half-lives of drug,
whichever period of time is longer

- Need for acute psychiatric hospitalization or is suicidal in the opinion of the study
physician

- Significant communicative impairments that would affect participation in clinical
trial

- Central nervous system abnormalities (e.g., cerebral aneurysm), seizures (convulsions,
epilepsy), Tourette's syndrome or presence of motor tics, or abnormal
electroencephalograms

- Lack of appetite that results in significant unintentional weight loss as determined
by the study physician in the last three months

- Uncontrolled hyperthyroidism

- Any cardiovascular or cerebrovascular abnormality deemed to be clinically significant
by the study physician, tachycardia (heart rate > 100 beats per minute), or
uncontrolled hypertension (defined as medication non-compliance or past 3 months with
a diastolic reading > 105 mm Hg), at the time of screening

- Closed angle glaucoma or pheochromocytoma

- Women with childbearing potential

- Current participation in a clinical trial or study that may add significant burden or
affect study outcomes

- Any condition that, in the opinion of the study physician, makes it medically
inappropriate or risky for the potential participant to enroll in the trial,
including, but not limited to, contraindication to treatment with methylphenidate.